All In Biotech

Drug Trial Radar · NCT04897516

Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease

Phase III Randomized,Multicenter Non-inferiority Study to Evaluate the Efficacy and Safety of Shorter Benznidazole Regimens Compared to the Standard Regimen to Treat Adult Patients With Chronic Chagas Disease

Last checked: Nov 20, 2026Latest source record: Nov 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jul 28, 2021

Primary completion

Jun 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Laboratorio Elea Phoenix S.A.Industry
Sponsor type
Industry
Collaborators
Drugs for Neglected Diseases
First posted
May 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chagas disease, a parasitic infection caused by Trypanosoma cruzi, is endemic in much of Latin America and affects people throughout the world. Currently treatment with the only two drugs effective against the infection, benznidazole and nifurtimox, has significant limitations including frequent adverse effects in adult patients. However, timely treatment is key to achieving global objectives of controlling the disease. The standard treatment has a long duration (60 days). NuestroBen will test the hypothesis that shorter treatment regimens of 14 days and 28 days will be non-inferior to the standard 60-day treatment while improving the safety profile.

Conditions

  • Chagas Disease

Interventions

  • Short regimen of benznidazoleDrug

    Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.

  • Short treatment with benznidazoleDrug

    Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks.

  • Standard treatment with benznidazoleDrug

    Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with sustained negativation of parasitemia according to the results of qualitative PCR testsTime frame: From the end of treatment, and up to 12 months of follow-up from the end of treatment.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben"

    Buenos Aires, Argentina · Not yet recruiting

  • Fundación Huésped

    Buenos Aires, Argentina · Recruiting

  • Hospital Francisco Javier Muñiz

    Buenos Aires, Argentina · Recruiting

  • Hospital Donación Francisco Santojanni

    Buenos Aires, Argentina · Not yet recruiting

  • Instituto de Cardiología de Corrientes "Juana Francisca Cabral"

    Corrientes, Argentina · Recruiting

  • Centro de Chagas y Patología Regional, Hospital Independencia

    Santiago del Estero, Argentina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.